Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Legend Biotech Corp ADR
(NQ:
LEGN
)
54.68
-2.40 (-4.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corp ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
August 12, 2024
Via
Benzinga
LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
August 09, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
August 08, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
August 01, 2024
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its...
Via
Benzinga
The Latest Analyst Ratings For Legend Biotech
July 15, 2024
Via
Benzinga
Assessing Legend Biotech: Insights From 15 Financial Analysts
June 21, 2024
Via
Benzinga
Unveiling 18 Analyst Insights On Legend Biotech
June 04, 2024
Via
Benzinga
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
July 26, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
July 21, 2024
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your...
Via
Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
July 20, 2024
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal.
Via
Talk Markets
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
July 18, 2024
Via
Benzinga
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
May 14, 2024
Via
Benzinga
Analyst Ratings For Legend Biotech
April 17, 2024
Via
Benzinga
CPI Data Sparks Rally in Biotech Stocks
July 15, 2024
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
July 10, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
July 02, 2024
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of...
Via
Benzinga
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
July 02, 2024
CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
June 17, 2024
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product.
Via
Benzinga
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
June 09, 2024
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.
Via
Benzinga
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
June 03, 2024
From
Legend Biotech
Via
Business Wire
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
May 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
May 13, 2024
In the last three months, IBRX outperformed NVDA by over 3x.
Via
Talk Markets
LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024
May 13, 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
May 13, 2024
From
Legend Biotech Corporation
Via
Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
April 22, 2024
From
Legend Biotech Corporation
Via
Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
April 19, 2024
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel
Via
Benzinga
Exposures
Product Safety
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
April 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
April 08, 2024
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.